Related Experiment Video
Updated: Oct 3, 2025
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Targeting GNAQ/11 through PKC inhibition in uveal melanoma
Caressa D Lietman1, Meredith McKean2
1Sarah Cannon Research Institute, 1100 Dr. Martin Luther King Jr. Blvd., Suite 800, Nashville, TN, 37203, USA.
Abstract:
Uveal melanoma is a rare malignancy affecting 5.1 patients/million per year with definitive treatment options of enucleation or radiation therapy to the primary tumor. Unfortunately, no FDA-approved systemic therapies exist for patients in the adjuvant or metastatic setting. Molecular profiling over the past decade has helped define uveal melanomas by characteristic mutations: GNAQ, GNA11, BAP1, SF3B1, and EIF1AX mutations. GNAQ/11 mutations are present in over 90% of patients with uveal melanoma and lead to signal transduction through G-protein coupled receptors to downstream growth factors. PKC inhibition has been an active area of investigation targeting this pathway specific to uveal melanoma. Several molecules have been developed and evaluated in clinical trials. Responses have been noted but clinical development has also yielded multiple toxicities and pathways of resistance limiting both breadth and durability of responses leading to combination therapy approaches. PKC inhibition remains an active and encouraging area of research to determine effective therapies for patients with uveal melanoma.
Insights
Uveal melanoma lacks effective systemic treatments. Targeting the GNAQ/11 mutation pathway with protein kinase C (PKC) inhibitors shows promise, but toxicities and resistance necessitate combination therapies for better uveal melanoma outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Ophthalmology
Background:
- Uveal melanoma is a rare eye cancer with limited treatment options.
- No FDA-approved systemic therapies exist for advanced or adjuvant uveal melanoma.
- Key mutations (GNAQ, GNA11, BAP1, SF3B1, EIF1AX) characterize uveal melanoma.
Purpose of the Study:
- To review the role of protein kinase C (PKC) inhibition in uveal melanoma treatment.
- To discuss the development of PKC inhibitors and their clinical trial outcomes.
- To explore challenges like toxicity and resistance in PKC inhibitor therapy for uveal melanoma.
Main Methods:
- Review of clinical trials and molecular profiling data for uveal melanoma.
- Analysis of signal transduction pathways involving GNAQ/11 mutations.
- Evaluation of PKC inhibitor efficacy, toxicity, and resistance mechanisms.
Main Results:
- GNAQ/11 mutations are prevalent in over 90% of uveal melanoma cases.
- PKC inhibition targets a key pathway in uveal melanoma.
- Clinical trials show some response to PKC inhibitors but also significant toxicities and resistance.
Conclusions:
- PKC inhibition is a promising therapeutic strategy for uveal melanoma.
- Combination therapy approaches are needed to overcome toxicity and resistance.
- Further research into PKC inhibition is crucial for developing effective uveal melanoma treatments.
